Category: Bedfont news

Giving Opportunity, Gaining Innovation: Women Driving the Future of Med-Tech

Posted on

Bedfont® Scientific Limited believes balanced teams drive better decision-making, stronger innovation, and long-term success.

Bedfont® Scientific Limited, a well-established Med-Tech company with over 49 years of expertise in the design and manufacture of medical breath analysis devices, is celebrating the women driving innovation in the Med-Tech industry this International Women’s Day (IWD). IWD is an annual event that celebrates women’s achievements and raises awareness about gender equality. In 2026, IWD celebrates 115 years of raising awareness of discrimination and taking action to forge gender parity.

International Women's Day 2026

This year’s theme, ‘Give to gain’, highlights the power of reciprocity and support. By giving women equal access to leadership opportunities, Bedfont® has built a diverse and balanced team. Today, women make up 50% of the workforce and nearly half of the companies’ 18 managers, proof that inclusion creates tangible gains for people and performance alike.

Switzerland is leading the way in Med-Tech, with women accounting for 40% of the industry’s workforce1. However, research published in 2024 shows that among the 78 largest medical device companies in Europe, only 24.4% of leadership positions are held by women2, highlighting the ongoing need for greater gender equality at senior levels.

“In a world where women in business have far greater opportunities than in our ancestors’ time, we are now seeing women actively driving the future of MedTech through innovation, leadership and scientific excellence. I am incredibly proud that nearly half of the leadership team at Bedfont are women, clear evidence that inclusion fuels both performance and progress. Representation matters, not only within our industry but for the next generation watching.” Comments Natasha Smith, Chief Operating Director at Bedfont®. “As a mother of two daughters, I want them to grow up proud, strong and confident enough to make their own mark in science, technology and beyond. On this International Women’s Day, with this year’s theme “Give to Gain,” we recognise that by investing in, training and championing women, we are shaping the future of MedTech and creating lasting impact for generations to come.”

This International Women’s Day, Bedfont® is celebrating the strength of a balanced workforce by recognising the women across the organisation with sustainably sourced chocolate from local business N2 Sweets Lab. This initiative reflects the company’s broader commitment to sustainability while supporting both local businesses and third-party partners worldwide, reinforcing a give-to-gain approach that benefits people, communities, and the planet.

To learn more about Bedfont® and its commitment to improving healthcare worldwide, visit the website here.

References

  1. Medtech Sector Study 2024 [Internet]. Swiss Medtech. 2024. Available from: https://www.swiss-medtech.ch/en/news/medtech-sector-study-2024
  2. Kirsh D. Women gain ground in medtech leadership, but parity remains far off [Internet]. Medical Design and Outsourcing. 2025 [cited 2026 Feb 10]. Available from: https://www.medicaldesignandoutsourcing.com/women-gain-ground-in-medtech-leadership-but-parity-remains-far-off/

Bedfont® Scientific Limited partners with Rymindr to deliver vital classroom supplies

Posted on

Bedfont® ensures exercise books reach UK classrooms through sponsorship.

Bedfont® Scientific Limited, a world leader in breath analysis, with nearly 50 years of expertise in the medical device industry, has teamed up with Rymindr, a social-tech company, to deliver vital classroom supplies. Rymindr is an app that lets users track important dates and access rewards. Through the app, Rymindr helps UK schools save money by sharing its profits. Bedfont® is proud to support its exercise book sponsorship campaign by sponsoring 20 boxes of exercise books, ensuring they reach the classrooms where they are needed.

It has been reported that over 70% of schools in the UK are underfunded1, leading to increased pressure on schools through teacher shortages and reduced resources. Rymindr’s mission is to build a single ecosystem that benefits all, leading to positive impacts on society and the environment for this generation and those to come. They have been funding breakfasts, school meals, and classroom supplies for children.

“We’re thrilled to partner with Bedfont® to get essential classroom supplies into UK schools. With budgets under pressure, simple items like classroom resources from exercise books to pencils shouldn’t be a struggle to fund, and this sponsorship will make a real difference in classrooms across the country.” Said Rav Panesar, CEO of Rymindr. “We’re incredibly grateful to Bedfont® for stepping up and sponsoring. This is exactly the kind of community impact we want to create through Rymindr, bringing businesses and schools together to deliver practical support where it’s needed most.”

Bedfont® is supporting their current initiative to get thousands of brand-new exercise books directly into UK primary schools. Having already distributed 4,000 boxes across the country, Rymindr were unfortunately notified at the end of 2025 that their storage facility was being sold. This has led to the launch of their latest sponsorship campaign, inviting individuals and businesses to sponsor boxes of books. The sponsorship covers the practical logistics, such as storage, pallet handling, and distribution.

Bedfont® Helps Deliver Classroom Supplies

“We’re incredibly proud to support this campaign and help deliver something as fundamental as exercise books to classrooms across the UK.” Said Jason Smith, CEO at Bedfont®. “With so many schools facing funding pressures, it’s vital we step in where we can. By sponsoring these boxes, we’re helping teachers focus on what matters most, teaching, while easing some of the financial strain they face every day. Education is the foundation of our future, and we’re committed to playing our part.”

Rymindr is matching each sponsored box, meaning schools across the UK are saving around £100 per box, which will really make a difference to the already stretched school budgets. Bedfont® is strongly committed to supporting the local community and is pleased to assist Rymindr in its latest initiative, providing much-needed exercise books to UK schools. To find out more about Rymindr, visit the website here. For more information on Bedfont® and its community initiatives, visit the website here.

References

  1. New data finds that 7 in 10 schools in England faced budget cuts since 2010 | National Education Union [Internet]. National Education Union. 2025. Available from: https://neu.org.uk/latest/press-releases/new-data-finds-7-10-schools-england-faced-budget-cuts-2010

Bedfont® Scientific Limited is pleased to support a major milestone to improve asthma care

Posted on

Intermedical UK proudly delivers the 3,000th NObreath® FeNO device to the UK market.

Bedfont® Scientific Limited, a medical device manufacturer based in Kent, with over 49 years’ experience in the breath analysis industry, was pleased to support its UK distributor, Intermedical UK, in supplying the 3,000th NObreath® Fractional exhaled Nitric Oxide (FeNO) device in the UK. Intermedical UK, a trusted leader in respiratory health, has been providing cardio-respiratory diagnostic and therapy equipment for frontline care since 1997.

Bedfont® support major milestone in asthma care. Bedfont Supports FeNO Milestone.
Bedfont® and Intermedical Team

Livio Gagliardi, Acting Managing Director at Intermedical (UK) Ltd, said, “Reaching the 3,000th NObreath® FeNO device in the UK is a shared success that reflects the dedication of both the Intermedical and Bedfont® teams. Together, we have worked hard to deliver a clinically proven, accessible, and cost-effective FeNO solution that genuinely meets the needs of frontline healthcare. We are incredibly grateful to our customers for placing their trust in us and for recognising the value that NObreath® brings to asthma diagnosis and ongoing management. Their commitment to improving respiratory care is what makes milestones like this possible, and we look forward to continuing this journey of innovation and impact alongside Bedfont®.”

NObreath FeNO device. Bedfont Supports FeNO Milestone.

The NObreath® FeNO device, manufactured by Bedfont®, is an innovative diagnostic tool that measures airway inflammation and helps healthcare professionals diagnose and manage asthma effectively. With over 3,000 devices now available across the UK, access to FeNO testing is improving, bringing Bedfont® closer to a world where everyone can access instant, non-invasive, and simple breath testing to support medical diagnosis.

As a valued long-term distributor of the NObreath®, Intermedical UK has played a key role in expanding access to high-quality respiratory diagnostics, and the close partnership over the years has been instrumental in reaching this monumental milestone.

Jason Smith, CEO at Bedfont®, comments, “This milestone of 3,000 devices in UK primary care highlights just how rapidly objective asthma testing is advancing. The updated joint UK guidelines now place even greater emphasis on FeNO, echoing the global shift toward evidence-based, accessible diagnostic tools. We are committed to making this technology available everywhere it is needed, ensuring clinicians and patients around the world benefit from fast, non-invasive breath testing.”

Bedfont® remains committed to improving asthma care worldwide, working closely with a global network of distributors to expand access to FeNO testing and improve asthma treatment. Recent partnerships in Mexico and India are already strengthening diagnostic capabilities, enabling clinicians in these regions to integrate simple, non-invasive breath testing into routine asthma assessment.

To learn more about Bedfont® and the NObreath® FeNO device, visit the website here.

coVita™ and Allergy Partners team up to improve asthma care in America

Posted on

Innovative NObreath® FeNO device is the allergists’ device of choice in the USA.

coVita™ LLC, a leader in advanced breath analysis and diagnostic solutions, serves as the U.S. distributor for the innovative NObreath® Fractional Exhaled Nitric Oxide (FeNO) device from UK-based Bedfont® Scientific Ltd. The new agreement with Allergy Partners marks the culmination of a strategic partnership developed over the past two years.

“The partnership established between coVita™ and Allergy Partners marks important progress in broadening access to FeNO technology on a global scale.” Said Jason Smith, CEO at Bedfont®. “We are pleased to support this collaboration and proud of the role coVita™ is playing in advancing high-quality asthma care.”

NObreath® device is allergists' device of choice in the USA.
Taking a FeNO test with the NObreath®

As the nation’s largest and most trusted integrated network of allergy and asthma specialists, Allergy Partners serves patients through more than 125 locations in over 20 states. Under the new agreement, all Allergy Partners clinics will provide FeNO testing with the NObreath® device, enhancing patient access to advanced, non-invasive tools that aid in asthma diagnosis and management. The NObreath® is the allergist’s device of choice in the USA, further underscoring its value in supporting accurate assessment and personalised treatment. With 26.8 million Americans, 8.2% of the U.S. population, affected by asthma in 2022, the need for innovative tools to support better care and disease management has never been greater.

“We are incredibly proud of our collaboration with Allergy Partners and thrilled to help them implement the NObreath® FeNO technology”, said Jason Aversano, CEO at coVita™.  “Their determination to integrate FeNO testing across their entire network of providers is illustrative of their understanding of the vital role objective FeNO monitoring plays in the modern clinical setting.”

Bedfont® Scientific, manufacturer of the NObreath®, and coVita™, share a long-standing partnership grounded in mutual respect, trust, and a shared vision to improve respiratory health through innovation. Over the years, the two companies have worked hand in hand to make advanced breath analysis more accessible to clinicians and patients throughout the United States. Their collaboration continues to exemplify how aligned values and global cooperation can drive meaningful change in healthcare.

To learn more about the NObreath® FeNO device, visit the website here.

References

  1. CDC. Most Recent Asthma Data [Internet]. Asthma Data. 2024. Available from: https://www.cdc.gov/asthma-data/about/most-recent-asthma-data.html

Bedfont® Scientific Limited is proud to exhibit cutting-edge breath analysis devices at WHX Dubai.

Posted on

Smokerlyzer®, Gastrolyzer®, and NObreath® devices on show at the world’s largest healthcare event.

Bedfont® Scientific, world leaders in breath analysis, with over 49 years of experience in the medical breath analysis industry, is thrilled to be showing its innovative devices at this year’s World Health Expo (WHX) Dubai, from the 9th to the 12th February 2026. Formally known as Arab Health, WHX Dubai has grown into a global healthcare hub, attracting professionals from over 180 countries. The event is due to take place at the Dubai Exhibition Centre.

Bedfont® exhibit at WHX Dubai
Bedfont Team at Arab Health 2025

WHX Dubai represents a cornerstone event for international healthcare collaboration, innovation, investment, and knowledge sharing. Bedfont® is pleased to be demonstrating its devices at the world’s largest healthcare event. On show at stand S7.F90.F, you will find the Smokerlyzer® range of breath carbon monoxide (CO) devices, which aid smoking cessation. The Gastrolyzer® hydrogen-methane breath testing (HMBT) range, which is used to help detect gastrointestinal disorders. And the NObreath® fractional exhaled nitric oxide (FeNO) device, which aids asthma diagnosis and management.

Jason Smith, CEO at Bedfont® Scientific, said, “WHX Dubai continues to set the benchmark for healthcare innovation worldwide. Our presence underscores our dedication to excellence and to delivering devices that genuinely elevate the standard of patient care. As healthcare demands grow, we remain committed to providing solutions that empower clinicians, improve outcomes, and support a more efficient, responsive care environment. We look forward to building on the momentum generated at this year’s event.”

WHX Dubai 2026 is expected to attract over 235,000 professionals, offering the opportunity to see innovative medical solutions, attend educational and thought-leadership conferences, and network with like-minded individuals looking to improve healthcare across the globe. With strong relationships already established across the Middle East, Bedfont® hopes to engage with various healthcare professionals during the event, showcasing its innovative breath analysis devices.

You will find the friendly Bedfont® team at stand S7.F90.F. For more information on Bedfont® and to learn more about the Smokerlyzer®, Gastrolyzer®, and NObreath® devices, visit the website here.

Setting the standard for wellbeing: Kent Business Awards celebrate Bedfont® Scientific Limited’s impact

Posted on

Bedfont® is recognised for putting people first and scoops the AHM Health & Wellbeing Award.

Bedfont® Scientific Limited, an innovative MedTech company that has just celebrated its 49th anniversary, is thrilled to have won the All Health Matters (AHM) Health & Wellbeing Award at this year’s Kent Business Awards. The annual awards celebrate business excellence across Kent, recognising the impact businesses have made over the year across various categories.

Setting the standard for wellbeing: Kent Business Awards celebrate Bedfont® Scientific Limited’s impact
Photo Credit: Albane McGuinness

Bedfont® prides itself on being a company that puts its people first, with a strong commitment to employee health and wellbeing. It has a dedicated team of Wellbeing Warriors, all Mental Health First Aid-trained, who work to ensure all staff are supported and encouraged to take time out of their busy days to focus on their wellbeing.

Claire Dadswell, Wellbeing Manager at Bedfont®, comments, “At Bedfont®, our people truly come first. We believe that when our team feels supported, nurtured, and valued, everything else follows. Our Wellbeing Warriors are here to make sure every member of staff knows it’s okay to pause, breathe, and prioritise themselves, because wellbeing isn’t just something we talk about, it’s something we live every day. We’re incredibly grateful to receive this award, as it recognises the dedication and hard work our team puts into supporting one another.”

Bedfont® joined various businesses from across Kent at the event, which took place at the Ashford International Hotel on Thursday, 4th December. The evening shone a light on the significant contribution businesses in Kent are making, from start-ups to Medium Business of the Year.

The award win is just another step forward in Bedfont’s efforts to prioritise staff wellbeing. Looking ahead, the Wellbeing Warriors are working hard to ensure 2026 is another positive year, with plans already in place to ensure staff feel valued and looked after.

For more information on Bedfont’s wellbeing initiatives, follow them on social media or visit the website here.

Life-saving Christmas present arrives early at Medway United FC

Posted on

Bedfont® Scientific Limited strengthens community safety with defibrillator donation.

Bedfont® Scientific Limited, an innovative MedTech company with over 48 years of experience in breath analysis, has proudly donated a defibrillator to Medway United FC. The club is an integral part of the football community in Medway and Kent, and the addition of a defibrillator ensures the safety of not only the club’s teams but also the surrounding community.

Bedfont® Scientific, a business committed to supporting the community, has strong ties with Medway United Football Club. Not only does the company sponsor the under-11s girls’ football team, but its very own CEO, Jason Smith, coaches the girls. When Jason heard that the grant the club were waiting for was taking longer than expected, he reached out to Defib Supplies, a crucial division of Intermedical (UK) Limited, who were happy to assist and provide the much-needed defibrillator at a reduced cost.

Jason Smith, CEO at Bedfont®, said, “As sponsors and as part of the coaching team, I see every week how much passion and commitment go into this club. When we learned that the defibrillator grant had been delayed, we felt a responsibility to act. We’re grateful to Defib Supplies for helping us secure the equipment at a reduced price, ensuring everyone at the club has access to the safest possible environment.”

In the UK, approximately 80,000 out-of-hospital cardiac arrests happen each year1, with less than 1 in 10 people surviving2. Having access to a defibrillator can increase survival by over 70% if used within the first three to five minutes2, and with cardiac arrest being the leading cause of sudden death during sport in young athletes3, the importance of having access to this life-saving equipment at all sports and health facilities is essential.

“We are incredibly grateful to Bedfont® Scientific for this generous donation. Having a defibrillator at our all-girls venue provides an invaluable level of safety and reassurance for players, parents, and coaches alike. It gives our young athletes the peace of mind to enjoy their football in the safest possible environment.” Said Mark Davis, Lead Coach and Founder at Medway United FC. “The addition of this life-saving equipment reflects our responsibility as a club to protect every young person who steps onto our pitch, and Bedfont’s support has helped us strengthen that commitment. Their generosity will have a lasting impact on our community.”

Bedfont’s generous donation provides the club with earlier access to this vital equipment and gives them peace of mind that, in the event of a sudden cardiac arrest, they have access to a tool that could save someone’s life.

To learn more about Bedfont® and its community efforts, visit the website here.

References

  1. Pareek N, Rees P, Quinn T, Von Vopelius-Feldt J, Gallagher S, Mozid A, et al. British Cardiovascular Interventional Society Consensus Position Statement on Out-of-Hospital Cardiac Arrest 1: Pathway of Care. Interventional Cardiology: Reviews, Research, Resources. 2022 Nov 10;
  2. NICE. Cardiac arrest – out of hospital care: What is the prognosis? [Internet]. NICE. 2018. Available from: https://cks.nice.org.uk/topics/cardiac-arrest-out-of-hospital-care/background-information/prognosis/
  3. ‌Mayo Clinic Staff. What to know about sudden death in young people [Internet]. Mayo Clinic. 2019. Available from: https://www.mayoclinic.org/diseases-conditions/sudden-cardiac-arrest/in-depth/sudden-death/art-20047571

Bedfont® Scientific Limited Expands Global Access to FeNO Testing in India

Posted on

Rbeck Healthtech Private completes registration for the NObreath® FeNO device, helping to improve asthma care across the region.

Bedfont® Scientific Limited, world leaders in breath analysis, with over 48 years of experience in designing and manufacturing medical breath analysis devices, has collaborated with Rbeck Healtech Private to make Fractional exhaled Nitric Oxide (FeNO) testing more accessible in India. Rbeck Healthtech Private is an entirely diverse healthcare equipment distributor, with a portfolio specialising in pulmonology, cardiology, and rehabilitation. It has recently added the innovative NObreath® device to its offerings, expanding access to FeNO testing in India.

Asthma is a chronic lung disease which cannot be cured; however, with the correct diagnosis and treatment, people with asthma can lead normal lives. India accounts for approximately 13.1% of the global asthma burden1, meaning that improving access to essential diagnostic and management tools, such as the NObreath®, is vital. The NObreath® measures FeNO levels on exhaled breath, a key indicator in type 2 airway inflammation, which is commonly found in asthma.

Jason Smith, CEO at Bedfont®, comments, “Partnering with Rbeck Healthtech and the successful registration for the NObreath® in India is a meaningful milestone in our mission to make precision asthma care accessible worldwide. India faces a significant burden of asthma, and we believe that FeNO testing can empower clinicians with clearer insights into airway inflammation, leading to more personalised and effective treatment decisions.”

With the Global Asthma Report 2022 indicating that a considerable proportion of asthmatic individuals remain underdiagnosed or untreated2 in India, it is hoped that this strategic partnership will help expand the accessibility of FeNO testing in the region, ultimately saving lives.

To find out more about the NObreath® and how it is improving asthma care worldwide, visit the website here.

References

1.Singh S, Salvi S, Mangal DK, Singh M, Awasthi S, Mahesh PA, et al. Prevalence, time trends and treatment practices of asthma in India: the Global Asthma Network study. ERJ Open Research [Internet]. 2022 May 30;8(2):00528-2021. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149387/

2.The Global Asthma Report 2022 [Internet]. Globalasthmareport.org. 2022 [cited 2025 Oct 8]. Available from: https://globalasthmareport.org/regions/india.php?

Clinical guidelines on FeNO

Posted on

Fractional exhaled Nitric Oxide (FeNO) is extensively utilised in both primary and secondary care settings worldwide. Many regions recommend FeNO-guided management as part of their clinical protocols. This article reviews FeNO-related guidelines in the UK and internationally, with a focus on comparing approaches across different regions.

Guidelines

NICE, BTS, and SIGN guidelines1:

The latest and most significant updates to UK guidelines were in November 2024, when the National Institute for Health and Care Excellence (NICE), the British Thoracic Society (BTS), and the Scottish Intercollegiate Guidelines Network (SIGN) updated and published a joint guideline on asthma diagnosis, monitoring, and chronic asthma management. Before this, NICE, BTS, and SIGN published their guidelines independently, the newly published guidelines bring harmonisation across the board. This review brings significant changes to asthma care approaches, including applying FeNO testing- an objective airway inflammation test for aiding in asthma diagnosis and management.

The guideline can be read here.

ERS guidelines2:

In 2022, the European Respiratory Society (ERS) updated its guidelines for the diagnosis of asthma in adults. In patients suspected of asthma, in whom the diagnosis is not established based on the initial spirometry combined with bronchodilator reversibility testing, ERS suggest measuring FeNO as part of the diagnostic work-up of adults aged > 18 years old with suspected asthma (conditional recommendation for the intervention, moderate quality of evidence).

The guideline can be read here.

DGP guidelines3:

The German Respiratory Society (The Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin, DGP) is the largest and oldest medical professional organisation for respiratory disorders. The latest guidelines on asthma, published in 2023, titled ‘S2K guidelines for specialist diagnosis and therapy of asthma’. FeNO is described as an indispensable component of specialist asthma diagnostics.

The guideline can be read here.

ATS guidelines4,5:

In 2011, the American Thoracic Society (ATS) developed guidance on the interpretation of FeNO testing in adults and children (up to 12 years old). The latest update to the American Thoracic Society (ATS) regarding FeNO to guide the treatment of asthma was in 2021. The update includes FeNO testing being strongly recommended to manage asthma in patients, in addition to usual care.

The American College of Allergy, Asthma and Immunology (ACAAI) and the American Academy of Allergy, Asthma and Immunology (AAAAI), published a joint statement in 2012 in response to the ATS guidelines “The American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology formally recognize and support the 2011 ATS Clinical Practice Guideline on the Interpretation of Exhaled Nitric Oxide for Clinical Applications.”6.

 The guideline can be read here and here.

GINA guidelines7,8:

The Global Initiative for Asthma (GINA) works with healthcare professionals, patient representatives, and public health officials around the world to reduce asthma prevalence, morbidity, and mortality. GINA’s guidelines, which were updated in 2024, recognise FeNO as a useful biomarker for aiding in asthma diagnosis and management. The guideline provides ppb recommendations for diagnosis; however, for children, GINA does not specify exact cutoffs but acknowledges its role in guiding treatment.

The guideline can be read here and here.

Reimbursement for FeNO:

Each country has different policies regarding reimbursement for FeNO testing. In England, practices strive to accomplish maximal Quality and Outcomes Framework (QoF)9 points to maintain practice income and fund expenses such as the purchase and maintenance of equipment, for example, FeNO devices. Currently, the QoF requirement for diagnosis of asthma is spirometry and one other test, such as FeNO, bronchodilator reversibility or measures of variability. With the change in the BTS/SIGN/NICE guideline, this will change in line with the guideline recommendations, with the requirement that practices perform at least one objective test that indicates asthma. In adults initially, this could be FeNO or blood eosinophils; in children, the initial test must be FeNO.

Across Europe, reimbursement policies vary widely, depending on national health guidelines. In Germany, FeNO testing is endorsed in the national asthma guidelines; however, FeNO is not reimbursed by Statutory Health Insurance (SHI) in primary care settings. In North America, Medicare and Medicare Advantage plans provide reimbursement for FeNO testing if the test is deemed medically necessary by your healthcare professional10.

Why guidelines matter:

The use of asthma diagnosis and management guidelines in the application of FeNO is essential globally, to ensure standardised, evidence-based asthma management, tailored to varying healthcare infrastructures and patient demographics. These guidelines empower healthcare professionals to make informed decisions, enhancing the accuracy of asthma diagnosis and treatment. Established guidelines fosters consistency in care, contributing to sustainable healthcare costs, reducing misdiagnosis, and ultimately improving patient outcomes. It’s worth noting that besides the countries listed in this article, numerous others also have national guidelines, including Japan, Italy, China, France, Mexico, Spain, Malaysia, Australia, and many more!

Key Takeaways

NICE, BTS, SIGN guidelines1:

Diagnosis:

  • For adults, asthma can be diagnosed if FeNO levels are ≥ 50 ppb or higher, an increase from the previous NICE guideline’s 40 ppb or higher threshold.
  • For children, asthma can be diagnosed if FeNO levels are ≥ 35 ppb or higher. This has remained the same as the previous NICE guidelines.
  • FeNO testing is recommended as first-line testing in asthma diagnosis for adults and children.
  • If the first test is diagnostic, further diagnostic testing is not required.

Management:

  • FeNO testing has been acknowledged as a tool in asthma management.
  • It aids to inform healthcare professionals when changing or adjusting asthma therapy.
  • Recommend FeNO use for asthma monitoring in adults.

ERS guidelines2:

Diagnosis:

  • A cut-off of 40 ppb offers the best compromise between sensitivity and specificity while a cut-off of 50 ppb has a high specificity of > 90% and is therefore supportive of asthma diagnosis.
  • A FeNO value < 40 ppb does not rule out asthma, and similarly, high FeNO levels themselves do not define asthma.

Management:

  • Measure FeNO as part of the diagnostic work-up of adults aged 18 years with suspected asthma (conditional recommendation for the test, moderate quality of evidence).

DGP guidelines3:

Diagnosis:

  • Low FeNO levels < 25 ppb (< 20 ppb in children) can be used to indicate that eosinophilic inflammation and responsiveness to corticosteroids are less likely.
  • High FeNO levels > 50 ppb (> 35 ppb in children) can be used to indicate that eosinophilic inflammation and, in symptomatic patients, responsiveness to corticosteroids are likely.

Management:

  • Patients with elevated FeNO levels are usually ICS-responsive. Elevated FeNO levels (especially FeNO levels > 50 ppb) during ICS therapy, despite clinical stability, argue against reducing the ICS dose.
  • In children and adolescents, regularly monitored FeNO proved to be a meaningful parameter to predict asthma relapse after planned ICS discontinuation, even before the onset of clinical symptoms.

ATS guidelines4,5:

Diagnosis:

  • Low FeNO levels < 25 ppb (< 20 ppb in children) can be used to indicate that eosinophilic inflammation and responsiveness to corticosteroids are less likely.
  • Intermediate FeNO values between 25 ppb and 50 ppb (20 ppb and 35 ppb in children) should be interpreted cautiously and with reference to the clinical context.
  • High FeNO levels > 50 ppb (> 35 ppb in children) can be used to indicate that eosinophilic inflammation and, in symptomatic patients, responsiveness to corticosteroids are likely.

Management:

  • FeNO is beneficial and should be used in addition to usual care.
  • Recommend the use of FeNO in monitoring airway inflammation in patients with asthma.

GINA guidelines7,8:

Diagnosis:

  • High FeNO levels > 50 ppb in non-smokers are moderately associated with eosinophilic airway inflammation.
  • FeNO levels above ≥ 20 ppb in adults with who have difficult-to-treat or severe asthma support the presence of type 2 airway inflammation.

Management:

  • Measure FeNO as an adjunct to diagnostic evaluation in individuals with suspected asthma and to monitor airway inflammation.

FeNO testing with the NObreath®:

Regular FeNO measurements indicate levels of airway inflammation, which can help healthcare professionals personalise treatment plans for patients by helping titrate ICS dosing and evaluate patient adherence to treatment.

For over 48 years, Bedfont® Scientific Limited has specialised in designing and manufacturing breath analysis medical devices. Using innovative technology, we provide cutting-edge medical devices at affordable prices to improve accessibility and healthcare standards worldwide. Bedfont® manufactures the NObreath® FeNO device, a non-invasive breath testing device which can be used to measure airway inflammation for the diagnosis and management of asthma.

For more information on the NObreath® and FeNO testing, visit the NObreath® website.

References:

  1. Asthma pathway (BTS, NICE, SIGN) [Internet]. National Institute for Health and Care Excellence. 2024. [Cited Friday 17th January 2025]. Available from: https://www.nice.org.uk/guidance/ng244
  2. Louis R, Satia I, Ojanguren I, Schleich F, Bonini M, Tonia T, Rigau D, Ten Brinke A, Buhl R, Loukides S, Kocks JW. European Respiratory Society guidelines for the diagnosis of asthma in adults. European Respiratory Journal. 2022 Sep 1;60(3). DOI: 10.1183/13993003.01585-202.
  3. Lommatzsch M, Criée CP, de Jong CC, Gappa M, Geßner C, Gerstlauer M, Hämäläinen N, Haidl P, Hamelmann E, Horak F, Idzko M. Diagnosis and treatment of asthma: a guideline for respiratory specialists 2023-published by the German Respiratory Society (DGP) e. V. Pneumologie (Stuttgart, Germany). 2023 Jul 5. DOI: 10.1055/a-2070-2135.
  4. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, Olin AC, Plummer AL, Taylor DR, American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. American journal of respiratory and critical care medicine. 2011 Sep 1;184(5):602-15. PMCID: PMC4408724 PMID: 21885636.
  5. Khatri SB, Iaccarino JM, Barochia A, Soghier I, Akuthota P, Brady A, Covar RA, Debley JS, Diamant Z, Fitzpatrick AM, Kaminsky DA. Use of fractional exhaled nitric oxide to guide the treatment of asthma: an official American Thoracic Society clinical practice guideline. American journal of respiratory and critical care medicine. 2021 Nov 15;204(10):e97-109. PMCID: PMC8759314 PMID: 34779751.
  6. Zitt M, Oppenheimer J, Bernstein D, Boggs P, Dinakar C, Jain N, Katial N, Sands M, Szefler S. AAAAI/ACAAI joint statement of support of the ATS clinical practice guideline: interpretation of exhaled nitric oxide for clinical applications. 2012 [Internet]. 2014.
  7. Global strategy for asthma management and prevention [Internet]. Global Initiative for Asthma. 2024. [Cited Friday 17th January 2025]. Available from: https://ginasthma.org/2024-report/
  8. Murugesan N, Saxena D, Dileep A, Adrish M, Hanania NA. Update on the role of FeNO in asthma management. Diagnostics. 2023 Apr 15;13(8):1428. DOI: 10.3390/diagnostics13081428.
  9. NHS England [Internet]. Quality and outcomes framework guidance for 24/25. 2024. [Cited 22nd April 2025]. Available from https://www.england.nhs.uk/publication/quality-and-outcomes-framework-guidance-for-2024-25/
  10. Healthline [Internet]. What you need to know abut FeNO testing for asthma. 2024. [Cited 22nd April 2025]. Available from: https://www.healthline.com/health/asthma/feno-test-asthma?c=1285499318383#takeaway

Leading By Example: Bedfont® Encourages Employee Well-being for World Well-being Week 2024

Posted on

World Well-being Week is dedicated to raising awareness about the importance of well-being in various aspects of life, including physical, mental, and emotional health. This year it takes place from June 24th to June 30th.

According to a recent study in 2023, personal well-being has declined, with the COVID-19 pandemic having a significant impact. Average ratings of well-being in the UK have declined across all measures between March 2022 and March 2023, with 57.41% of adults reporting high levels of anxiety and 46.6% reporting low levels of happiness1.

During World Well-being Week, companies are encouraged to support their employee’s well-being through various activities and resources. Workplace stress and burnout can significantly impact employee productivity and job satisfaction. Reports have shown that companies prioritising well-being have happier and more engaged employees, increasing workplace productivity and reducing employee absences.

Bedfont® have their very own team of Well-being Warriors, ensuring employees can take part in activities designed to reduce stress and enhance the workplace environment. Bedfont® is fully committed to well-being in the office and strives to promote and maintain the mental health and well-being of all employees, proving this by being presented with the Platinum Business Award by Kent County Council in April 2023, the highest award possible for promoting a positive work environment, and a health work/life balance.

In 2023, Bedfont® also opened their very own well-being garden, in memory of 2 well loved members of staff. The vision behind the garden is to give staff a special space to be able to enjoy, collect their thoughts, and de-stress.

Earlier this year, the Bedfont® Well-being Warriors were in full force for Stress Awareness Month, which occurs annually in April. The Warriors organised a week of stress-busting activities for staff, which included a virtual coffee morning, a stress-busting activity – Pictionary, a Wednesday walk, a Bedfont® bar with a music Kahoot quiz, and a healthy lunch. Employees were encouraged to join the activities and everyone thoroughly enjoyed themselves.

With personal well-being declining, it’s important, now more than ever, to ensure everything is being done to improve employee well-being. Here are some examples of how Bedfont® has been working to improve morale and well-being:

Well-being Gifts: Sending well-being packages or gifts to employees, such as stress balls, herbal teas, or wellness journals, to encourage them to take time for self-care.

Team Building Activities: Organising team-building activities that promote collaboration and social-well-being. These could be anything from group problem-solving challenges to fun games or social events.

Relaxation Spaces: Establishing relaxation zones in the workplace where employees can take short breaks to de-stress. These could include comfortable seating, ambient music, and access to mindfulness or meditation apps.

Healthy Eating Day: Promoting nutrition by hosting a healthy eating day. This could involve a workshop on nutritional information, providing healthy meals or snacks, or even organising a cooking demonstration focusing on healthy recipes.

Follow us on social media to keep up with all the news and information on what Bedfont® is doing to improve employee well-being.

  1. Personal well-being in the UK: April 2022 to March 2023. [Cited on 8/5/24] Available from https://www.ons.gov.uk/peoplepopulationandcommunity/wellbeing/bulletins/measuringnationalwellbeing/april2022tomarch2023#:~:text=Adults%20with%20%E2%80%9Cvery%20bad%E2%80%9D%20self,and%203.8%25%2C%20respectively
Back to top